Paula Lum, MD, MPH

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address2540 23rd Street, #4801
San Francisco CA 94110
ORCID ORCID Icon0000-0002-0833-8642 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityB.A.1985Human Biology
    Stanford UniversityM.A.1985Sociology
    Case Western Reserve UniversityM.D.1993Medicine
    University of California, San FranciscoResidency1996Primary Care Internal Medicine, SFGH
    University of California, BerkeleyM.P.H.1997Epidemiology
    University of California, San FranciscoFellowship1999AIDS Prevention Studies
    University of California, San Francisco2019Diversity, Equity, and Inclusion Champion Training
    Collapse Awards and Honors
    UCSF Division of HIV, Infectious Diseases & Global Medicine2024 Meg Newman Award for Teaching Excellence
    San Francisco General Hospital Medical Services2021John Murray Award for Academic Excellence and Dedication to the Mission of San Francisco General
    Association for Multidisciplinary Education and Research in Substance use and Addiction (AMERSA)2019W. Anderson Spickard, Jr. Excellence in Mentorship Award
    Drug Policy Alliance2019Norman E. Zinberg Award for Achievement in the Field of Medicine
    University of California, San Francisco2018Chancellor Award for Public Service, Faculty Nominee
    UCSF Chapter of AOA’s Class of 20112011Alpha Omega Alpha Honor Medical Society, Faculty Nominee
    Haile T. Debas Academy of Medical Educators, UCSF School of Medicine2007Excellence in Direct Teaching and/or Excellence in Mentoring and Advising Award
    UCSF Division of HIV/AIDS at San Francisco General Hospital2000Outstanding Teacher and Distinguished Lecturer Award
    Case Western Reserve University School of Medicine1993Alpha Omega Alpha Honor Medical Society
    American Medical Women’s Association1993Janet M. Glasgow Memorial Achievement Citation

    Collapse Overview 
    Collapse Overview
    Paula J. Lum, MD MPH is Professor of Clinical Medicine and founding Program Director of the UCSF Primary Care Addiction Medicine Fellowship. She has been a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at San Francisco General Hospital since 1999. Board certified in internal medicine and addiction medicine, Dr. Lum practices at the places where HIV, addiction, and poverty collide. Her research and clinical activities are grounded in evidence-based, patient-centered care to improve the health and well-being of the urban poor. Her current areas of focus include: (1) HIV and viral hepatitis prevention and treatment in persons who use drugs, (2) evidence-based interventions in primary care and non-traditional settings for unhealthy substance use and its complications, and (3) curricular interventions to provide health care professionals with the skills, knowledge, and confidence to offer effective patient-centered care to persons who use drugs.

    Collapse Research 
    Collapse Research Activities and Funding
    EMBOSS, NIDA CTN-0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder (MOUD)– A Pragmatic Hybrid Effectiveness/Implementation Trial
    NIH/NIDA 5UG1DA015831-22Aug 1, 2023 - May 31, 2029
    Role: Site Co-Principal Investigator
    UCSF Primary Care Addiction Medicine Fellowship Program Expansion
    DHHS/HRSA T25HP376120100Jul 1, 2020 - Jul 1, 2025
    Role: Principal Investigator
    Project HOUDINI LINK: Hospital Opioid Use Disorder treatment INItiation and LINKage to Care
    DHHS/SAMHSA H79T1081419Sep 30, 2018 - Sep 29, 2021
    Role: Co-Investigator
    Short-term and long-term effects of methamphetamine exposure on residual viral transcription during treated HIV disease
    NIH R61DA047024Aug 1, 2018 - May 31, 2022
    Role: Co-Investigator
    Patient-Centered Models of HCV Care for People who Inject Drugs
    PCORI HEPC-1503-28122Nov 1, 2015 - Jan 31, 2022
    Role: Site Principal Investigator
    SBIRT Interdisciplinary Training Program
    DHHS/SAMHSA U79TI025386-01Sep 1, 2014 - Aug 31, 2017
    Role: Co-Investigator
    Western States Node of the National Drug Abuse Treatment Clinical Trials Network, Protocols 0055 and 0067: Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES)
    NIH/NIDA 5U10DA015815-12Sep 30, 2013 - May 31, 2020
    Role: Co-Investigator
    Computer-Facilitated 5A's for Smoking Cessation in Primary Care
    NIH R01DA034253Jul 15, 2012 - Jun 30, 2018
    Role: Co-Investigator
    A Staged Phase I/II Study, to Assess Safety, Efficacy and Immunogenicity of a New Hepatitis C Prophylactic Vaccine Based on Sequential Use of AdCh3NSmut1 and MVA-NSmut
    NIH/NIAID HHSN2662040074CDec 1, 2010 - Sep 15, 2018
    Role: Site Principal Investigator
    Impact of a Computer-Assisted SBIRT Program in an HIV Care Setting
    NIH RC1DA028224Sep 30, 2009 - Aug 31, 2011
    Role: Co-Investigator
    A SBIRT Medical Residency Program at San Francisco General Hospital
    NIH U79TI020296Sep 30, 2008 - Jan 31, 2015
    Role: Principal Investigator
    Interaction of Alcohol and HAART in HIV/AIDS and HIV/AIDS and HCV Coinfection
    NIH R01AA018001Sep 30, 2008 - May 31, 2013
    Role: Co-Investigator
    Preparing Patients to Start Antiretroviral Therapy: A Randomized Controlled Trial
    NIH R01MH079700Jul 31, 2007 - May 31, 2013
    Role: Co-Investigator
    A couples-based approach to improving engagement in HIV care
    NIH R01NR010187Aug 15, 2006 - May 31, 2021
    Role: Co-Investigator
    Integrating Buprenorphine into the SFGH AIDS Program
    DHHS/HRSA H97HA03799Sep 1, 2004 - Dec 31, 2009
    Role: Principal Investigator
    A Randomized Trial of Vaccine Adherence in Young IDU
    NIH R01DA017476Sep 30, 2003 - Jun 30, 2008
    Role: Principal Investigator
    Providing Prevention: An Intervention for HIV Care Providers
    CDC R18/CCR920974Oct 1, 2002 - Sep 30, 2005
    Role: Co-Investigator
    Acute Hepatitis C Infection in Young Injectors
    NIH R01DA016017Sep 25, 2002 - Aug 31, 2020
    Role: Co-Investigator
    Intervention Research Addressing the Primary and Secondary Prevention Needs of HIV-Seropositive Injection Drug Users
    CDC U50/CCU918003-01Oct 1, 1999 - Mar 1, 2004
    Role: Co-Investigator
    HIV AND HEPATITIS IN YOUNG INJECTORS: A COMMUNITY STUDY
    NIH R01DA012803Sep 25, 1999 - Aug 31, 2003
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Current Self-reported Pain Before and After Cure of Hepatitis C Among Persons Who Actively Inject Drugs. J Addict Med. 2024 Oct 30. Tsui JI, Ludwig-Barron NT, James JR, Heo M, Sivaraj LB, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Falade-Nwulia O, Feinberg J, Kim AY, Norton B, Page K, Litwin AH. PMID: 39475112.
      View in: PubMed   Mentions:    Fields:    
    2. Variability of Hepatitis C Treatment Cascade Outcomes among People Who Inject Drugs across Geographically Diverse Clinics in the US: The HERO Study. Viruses. 2024 Sep 30; 16(10). Lopes SS, Heo M, Pericot-Valverde I, Norton BL, Taylor LE, Tsui JI, Mehta SH, Feinberg J, Kim AY, Lum PJ, Page K, Murray-Krezan C, Anderson J, Litwin AH. PMID: 39459883; PMCID: PMC11512280.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study. JAMA Netw Open. 2024 Aug 01; 7(8):e2430024. Litwin AH, Tsui JI, Heo M, Mehta SH, Taylor LE, Lum PJ, Feinberg J, Kim AY, Norton BL, Pericot-Valverde I, Arnsten J, Meissner P, Karasz A, McKee MD, Ward JW, Johnson N, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Carty J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Groome M, Davies S, Costello K, Page K, HERO Study Group. PMID: 39186268.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Effect of self-efficacy among persons who inject drugs treated with direct-acting antivirals on Hepatitis C treatment initiation, duration, completion, adherence, and cure. Drug Alcohol Depend. 2024 Sep 01; 262:111384. Lopes SS, Pericot-Valverde I, Dotherow JE, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH, HERO study group. PMID: 38991632.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. EXPLORATION OF HIV RISK BEHAVIORS AND ATTITUDES TOWARDS PREP AMONG PEOPLE WHO INJECT DRUGS BY GENDER AND SEXUAL ORIENTATION. Drug and Alcohol Dependence. 2024 Jul 1; 260:110036. Bhatraju BE, Tsui TJ, Radick RA, Heo HM, Sivaraj SL, Mehta MS, Lum LP, Taylor TL, Feinberg FJ, Kim KA, Norton NB, Pericot-Valverde PI, Page PK, Litwin LA. .
      View in: Publisher Site   Mentions:
    6. Substance use Attitudes, Beliefs, Experience, and Knowledge Among Nursing and Nursing Assistant Students. J Psychoactive Drugs. 2024 Apr 22; 1-11. Fokuo JK, Hutman PJ, Gruber VA, Masson CL, Lum PJ, Bush DM, Naugle JA, Sorensen JL. PMID: 38646910; PMCID: PMC11493843.
      View in: PubMed   Mentions:    Fields:    
    7. Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study. BMC Infect Dis. 2024 Feb 23; 24(1):251. Lopes SS, Pericot-Valverde I, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Karasz A, Arnsten J, Moschella P, Heo M, Litwin AH. PMID: 38395747; PMCID: PMC10893697.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    8. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study. J Hepatol. 2024 May; 80(5):702-713. Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten JH, Sprecht-Walsh S, Page K, Murray-Krezan C, Anderson J, Litwin AH, HERO Study Group. PMID: 38242324.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    9. Self-reported and measured adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs: The HERO study. Int J Drug Policy. 2024 Jan; 123:104288. Lopes SS, Pericot-Valverde I, Arnsten J, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Page K, Murray-Krezan C, Anderson J, Moschella P, Heo M, Litwin AH. PMID: 38103458.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    10. Shame and stigma in association with the HCV cascade to cure among people who inject drugs. Drug Alcohol Depend. 2023 Dec 01; 253:111013. Batchelder AW, Heo M, Foley JD, Sullivan MC, Lum P, Pericot Valverde I, Taylor LE, Mehta SH, Kim AY, Norton B, Tsui JI, Feinberg J, Page K, Litwin AH, HERO Study Group. PMID: 37951006.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    11. Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C Virus Infection: The HERO Study. Open Forum Infect Dis. 2023 Nov; 10(11):ofad498. Pericot-Valverde I, Lopes SS, Nahvi S, Thrasher JF, Karasz A, Taylor LE, Mehta SH, Lum PJ, Tsui JI, Page K, Feinberg J, Kim AY, Norton BL, Arnsten JH, Fernandez-Artamendi S, Heo M, Litwin A, HERO Research Group . PMID: 38023556; PMCID: PMC10644781.
      View in: PubMed   Mentions:
    12. A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences. J Med Internet Res. 2023 06 02; 25:e38176. Karasz A, Merchant K, Arnsten J, Feinberg J, Kim AY, Lum PJ, McKee MD, Mehta SH, Meissner P, Norton BL, Page K, Pericot-Valverde I, Singh R, Stein E, Taylor LE, Tsui JI, Wagner K, Litwin A. PMID: 37266986; PMCID: PMC10276322.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    13. Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs. Drug Alcohol Depend. 2023 06 01; 247:109878. Tsui JI, Lum PJ, Taylor LE, Mehta SH, Feinberg J, Kim AY, Norton BL, Niu J, Heo M, Arnsten J, Pericot-Valverde I, Thomas A, Blalock KL, Radick A, Murray-Krezan C, Page K, Litwin AH, HERO Study Group. PMID: 37150144.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    14. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial. Lancet Gastroenterol Hepatol. 2022 12; 7(12):1112-1127. Litwin AH, Lum PJ, Taylor LE, Mehta SH, Tsui JI, Feinberg J, Kim AY, Norton BL, Heo M, Arnsten J, Meissner P, Karasz A, Mckee MD, Ward JW, Johnson N, Pericot-Valverde I, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Roche J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Page K, HERO Study Group. PMID: 36370741.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    15. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. Addiction. 2022 07; 117(7):1961-1971. Korthuis PT, Cook RR, Lum PJ, Waddell EN, Tookes H, Vergara-Rodriguez P, Kunkel LE, Lucas GM, Rodriguez AE, Bielavitz S, Fanucchi LC, Hoffman KA, Bachrach K, Payne EH, Collins JA, Matthews A, Oden N, Jacobs P, Jelstrom E, Sorensen JL, McCarty D. PMID: 35129242; PMCID: PMC9314106.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    16. Meeting people where they are: implementing hospital-based substance use harm reduction. Harm Reduct J. 2022 02 09; 19(1):14. Perera R, Stephan L, Appa A, Giuliano R, Hoffman R, Lum P, Martin M. PMID: 35139877; PMCID: PMC8826677.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    17. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. Addict Sci Clin Pract. 2021 11 10; 16(1):67. Hoffman KA, Baker R, Fanucchi LC, Lum PJ, Kunkel LE, Ponce Terashima J, McCarty D, Jacobs P, Korthuis PT. PMID: 34758887; PMCID: PMC8579672.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    18. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. Drug Alcohol Depend. 2021 11 01; 228:109077. Cook RR, Torralva R, King C, Lum PJ, Tookes H, Foot C, Vergara-Rodriguez P, Rodriguez A, Fanucchi L, Lucas GM, Waddell EN, Korthuis PT. PMID: 34600253; PMCID: PMC8595584.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    19. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med. 2021 02 11; 384(6):541-549. Page K, Melia MT, Veenhuis RT, Winter M, Rousseau KE, Massaccesi G, Osburn WO, Forman M, Thomas E, Thornton K, Wagner K, Vassilev V, Lin L, Lum PJ, Giudice LC, Stein E, Asher A, Chang S, Gorman R, Ghany MG, Liang TJ, Wierzbicki MR, Scarselli E, Nicosia A, Folgori A, Capone S, Cox AL. PMID: 33567193; PMCID: PMC8367093.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    20. Dismantling racism against Black, Indigenous, and people of color across the substance use continuum: A position statement of the association for multidisciplinary education and research in substance use and addiction. Subst Abus. 2021; 42(1):5-12. Hagle HN, Martin M, Winograd R, Merlin J, Finnell DS, Bratberg JP, Gordon AJ, Johnson C, Levy S, MacLane-Baeder D, Northup R, Weinstein Z, Lum PJ. PMID: 33465013.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    21. Time to ACT: launching an Addiction Care Team (ACT) in an urban safety-net health system. BMJ Open Qual. 2021 01; 10(1). Martin M, Snyder HR, Coffa D, Steiger S, Clement JP, Ranji SR, Azari S, Nguyen OK, Lum PJ. PMID: 33500326; PMCID: PMC7843300.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    22. Accumulation of HIV-1 Drug Resistance Mutations and Methamphetamine Use. Curr HIV Res. 2021; 19(6):497-503. Truong HM, Fatch R, Deeks SG, Krone M, Martin JN, Hunt PW, Lum PJ. PMID: 34176462; PMCID: PMC10659984.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    23. Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Serv Res. 2019 Nov 21; 19(1):862. Hoffman KA, Baker R, Kunkel LE, Waddell EN, Lum PJ, McCarty D, Korthuis PT. PMID: 31752905; PMCID: PMC6868733.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    24. Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis C treatment for people who inject drugs: The HERO study. Contemp Clin Trials. 2019 12; 87:105859. Litwin AH, Jost J, Wagner K, Heo M, Karasz A, Feinberg J, Kim AY, Lum PJ, Mehta SH, Taylor LE, Tsui JI, Pericot-Valverde I, Page K, HERO Study Group. PMID: 31669450; PMCID: PMC7261375.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    25. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract. 2019 05 06; 14(1):20. Carter J, Zevin B, Lum PJ. PMID: 31060600; PMCID: PMC6501460.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    26. Computer-Facilitated 5A's for Smoking Cessation: A Randomized Trial of Technology to Promote Provider Adherence. Am J Prev Med. 2018 07; 55(1):35-43. Satterfield JM, Gregorich SE, Kalkhoran S, Lum PJ, Bloome J, Alvarado N, Muñoz RF, Vijayaraghavan M. PMID: 29929682; PMCID: PMC6020838.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    27. Continued Transmission of HIV Among Young Adults Who Inject Drugs in San Francisco: Still Room for Improvement. AIDS Behav. 2018 04; 22(4):1383-1394. Mirzazadeh A, Evans JL, Hahn JA, Jain J, Briceno A, Shiboski S, Lum PJ, Bentsen C, Davis G, Shriver K, Dimapasoc M, Stone M, Busch MP, Page K. PMID: 29168067; PMCID: PMC6054135.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. Development and differentiability of three brief interventions for risky alcohol use that include varying doses of motivational interviewing. Addict Sci Clin Pract. 2018 02 27; 13(1):6. Hettema JE, Cockrell SA, Reeves A, Ingersoll KS, Lum PJ, Saitz R, Murray-Krezan CM, Carrejo VA. PMID: 29482632; PMCID: PMC5828117.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    29. Opioids, Hepatitis C Virus Infection, and the Missing Vaccine. Am J Public Health. 2018 02; 108(2):156-157. Page K, Cox A, Lum PJ. PMID: 29320280; PMCID: PMC5846595.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    30. Changes in Specific Substance Involvement Scores among SBIRT recipients in an HIV primary care setting. Addict Sci Clin Pract. 2017 Dec 12; 12(1):34. Dawson-Rose C, Draughon JE, Cuca Y, Zepf R, Huang E, Cooper BA, Lum PJ. PMID: 29229000; PMCID: PMC5725890.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    31. 2017 HIV Medicine Association of Infectious Diseases Society of America Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With Human Immunodeficiency Virus. Clin Infect Dis. 2017 Oct 30; 65(10):1601-1606. Bruce RD, Merlin J, Lum PJ, Ahmed E, Alexander C, Corbett AH, Foley K, Leonard K, Treisman GJ, Selwyn P. PMID: 29091230; PMCID: PMC5850004.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    32. Integrated HIV care is associated with improved engagement in treatment in an urban methadone clinic. Addict Sci Clin Pract. 2017 08 22; 12(1):19. Simeone C, Shapiro B, Lum PJ. PMID: 28826401; PMCID: PMC5568716.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    33. Patterns of and reasons for electronic cigarette use in primary care patients. J Gen Intern Med. 2017 Oct; 32(10):1122-1129. Kalkhoran S, Alvarado N, Vijayaraghavan M, Lum PJ, Yuan P, Satterfield JM. PMID: 28710596; PMCID: PMC5602769.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    34. Prevalence and predictors of HCV among a cohort of opioid treatment patients in Dar es Salaam, Tanzania. Int J Drug Policy. 2017 07; 45:64-69. Lambdin BH, Lorvick J, Mbwambo JK, Rwegasha J, Hassan S, Lum P, Kral AH. PMID: 28628854; PMCID: PMC6166640.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    35. Disparities in receipt of 5As for smoking cessation in diverse primary care and HIV clinics. Prev Med Rep. 2017 Jun; 6:80-87. Vijayaraghavan M, Yuan P, Gregorich S, Lum P, Appelle N, Napoles AM, Kalkhoran S, Satterfield J. PMID: 28271025; PMCID: PMC5334546.
      View in: PubMed   Mentions: 28  
    36. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction. 2017 Jun; 112(6):1036-1044. Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, Sorensen JL, Arenas V, Ha D, Mandler RN, McCarty D, CTN-0055 CHOICES Investigators. PMID: 28061017; PMCID: PMC5408318.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    37. Extended-release naltrexone feasibility in HIV clinics: A pilot study. Drug and Alcohol Dependence. 2017 Feb 1; 171:e108. Korthuis KT, Lum LP, Vergara-Rodriguez VP, Ahamad AK, Wood WE, Lindblad LR, Mandler MR, Sorensen SJ, Ha HD, Oden ON, Kunkel KL, McCarty MD. .
      View in: Publisher Site   Mentions:
    38. A delayed injection-site reaction in a patient receiving extended-release naltrexone. Subst Abus. 2016 Apr-Jun; 37(2):278-80. Ahamad K, Korthuis PT, Lum PJ, Johnson C, Wood E. PMID: 26820699; PMCID: PMC5266530.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. A Longitudinal Study of Multiple Drug Use and Overdose Among Young People Who Inject Drugs. Am J Public Health. 2016 May; 106(5):915-7. Riley ED, Evans JL, Hahn JA, Briceno A, Davidson PJ, Lum PJ, Page K. PMID: 26985620; PMCID: PMC4878116.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    40. Comorbid substance use among persons with HIV and chronic pain. Chronic Pain and HIV. 2016 Mar 17; 78-96. Lum LP, Bruce BR. .
      View in: Publisher Site   Mentions:
    41. Prevalence of Substance Use in an HIV Primary Care Safety Net Clinic: A Call for Screening. J Assoc Nurses AIDS Care. 2017 Mar - Apr; 28(2):238-249. Dawson-Rose C, Draughon JE, Zepf R, Cuca YP, Huang E, Freeborn K, Lum PJ. PMID: 26763795; PMCID: PMC4903083.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    42. The longitudinal influence of multiple depressant use on nonfatal overdose among young people who inject drugs. Drug and Alcohol Dependence. 2015 Nov 1; 156:e190. Riley RE, Hahn HJ, Evans EJ, Briceno BA, Davidson DP, Lum LP, Page PK. .
      View in: Publisher Site   Mentions:
    43. Beyond the Ask and Advise: Implementation of a Computer Tablet Intervention to Enhance Provider Adherence to the 5As for Smoking Cessation. J Subst Abuse Treat. 2016 Jan; 60:91-100. Kalkhoran S, Appelle NA, Napoles AM, Munoz RF, Lum PJ, Alvarado N, Gregorich SE, Satterfield JM. PMID: 26150093; PMCID: PMC4670822.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    44. Using Interactive Web-Based Screening, Brief Intervention and Referral to Treatment in an Urban, Safety-Net HIV Clinic. AIDS Behav. 2015 Jun; 19 Suppl 2:186-93. Dawson Rose C, Cuca YP, Kamitani E, Eng S, Zepf R, Draughon J, Lum P. PMID: 25963770; PMCID: PMC4547536.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    45. Addressing Adolescent Substance Use: Teaching Screening, Brief Intervention, and Referral to Treatment (SBIRT) and Motivational Interviewing (MI) to Residents. Subst Abus. 2015; 36(3):325-31. Whittle AE, Buckelew SM, Satterfield JM, Lum PJ, O'Sullivan P. PMID: 25260121.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    46. A Skills-Based Curriculum for Teaching Motivational Interviewing-Enhanced Screening, Brief Intervention, and Referral to Treatment (SBIRT) to Medical Residents. MedEdPORTAL. 2015 Jan 1. Azari AS, Ratanawongsa RN, Hettema HJ, Cangelosi CC, Tierney TM, Coffa CD, Shapiro SB, Jain JS, Hersh HD, Manuel MJ, Ciccarone CD, Lum LP. .
      View in: Publisher Site   Mentions:
    47. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014 Dec; 174(12):1974-81. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. PMID: 25347412; PMCID: PMC4506774.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansPHPublic Health
    48. Higher risk of incident hepatitis C virus among young women who inject drugs compared with young men in association with sexual relationships: a prospective analysis from the UFO Study cohort. BMJ Open. 2014 May 29; 4(5):e004988. Tracy D, Hahn JA, Fuller Lewis C, Evans J, Briceño A, Morris MD, Lum PJ, Page K. PMID: 24875490; PMCID: PMC4039809.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    49. Ethnically diverse patients' perceptions of clinician computer use in a safety-net clinic. J Health Care Poor Underserved. 2013 Nov; 24(4):1542-51. Ratanawongsa N, Barton JL, Schillinger D, Yelin EH, Hettema JE, Lum PJ. PMID: 24185151; PMCID: PMC4554529.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr; 23(2):137-44. McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, DiFrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD. PMID: 24118434; PMCID: PMC3984379.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    51. Interactions between alcohol and the HIV entry inhibitor Maraviroc. J Int Assoc Provid AIDS Care. 2013 Nov-Dec; 12(6):375-7. Gruber VA, Rainey PM, Lum PJ, Beatty GW, Aweeka FT, McCance-Katz EF. PMID: 23881910; PMCID: PMC4100473.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    52. Interactions between alcohol and the antiretroviral medications ritonavir or efavirenz. J Addict Med. 2013 Jul-Aug; 7(4):264-70. McCance-Katz EF, Gruber VA, Beatty G, Lum PJ, Rainey PM. PMID: 23666322; PMCID: PMC3737351.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    53. 8. Implementing Sbirt in Pediatrics: Results of a Needs Assessment. Journal of Adolescent Health. 2013 Feb 1; 52(2):s18-s19. Buckelew BS, Whittle WA, Lum LP, O'Sullivan OP, Satterfield SJ. .
      View in: Publisher Site   Mentions:
    54. Smoking cessation interventions with female smokers living with HIV/AIDS: a randomized pilot study of motivational interviewing. AIDS Care. 2013; 25(7):820-7. Manuel JK, Lum PJ, Hengl NS, Sorensen JL. PMID: 23116051; PMCID: PMC3625696.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    55. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis. 2013 Feb; 56(3):405-13. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, Delwart E, Tobler L, Cox AL, Busch MP. PMID: 23090930; PMCID: PMC3540042.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    56. Untreated HIV infection is associated with higher blood alcohol levels. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):282-8. McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM. PMID: 22495786; PMCID: PMC3723399.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    57. Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. Am J Epidemiol. 2012 Feb 15; 175(4):302-8. Evans JL, Tsui JI, Hahn JA, Davidson PJ, Lum PJ, Page K. PMID: 22227793; PMCID: PMC3271816.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    58. A SBIRT curriculum for medical residents: development of a performance feedback tool to build learner confidence. Subst Abus. 2012; 33(3):241-50. Hettema JE, Ratanawongsa N, Manuel JK, Ciccarone D, Coffa D, Jain S, Lum PJ. PMID: 22738001; PMCID: PMC3412302.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    59. Expectancy and readiness-based predictors of treatment uptake among the urban poor living with HIV. J Acquir Immune Defic Syndr. 2011 Dec 15; 58(5):469-71. Johnson MO, Dilworth SE, Stephens E, Lum PJ, Neilands TB. PMID: 21926630; PMCID: PMC3215899.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    60. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis. 2011 Aug 02; 11:208. Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K. PMID: 21810243; PMCID: PMC3199778.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    61. Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report. J Assoc Nurses AIDS Care. 2012 Jan-Feb; 23(1):16-29. Asher A, Lum PJ, Page K. PMID: 21497111; PMCID: PMC3140618.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    62. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S22-32. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP, Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A, Botsko M, Nandi V, Gourevitch MN, Finkelstein R, BHIVES Collaborative. PMID: 21317590; PMCID: PMC3263431.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCellsCTClinical Trials
    63. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S33-8. Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG, BHIVES Collaborative. PMID: 21317592; PMCID: PMC3863630.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    64. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S54-61. Sullivan LE, Botsko M, Cunningham CO, O'Connor PG, Hersh D, Mitty J, Lum PJ, Schottenfeld RS, Fiellin DA, BHIVES Collaborative. PMID: 21317595; PMCID: PMC3065971.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    65. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S91-7. Lum PJ, Little S, Botsko M, Hersh D, Thawley RE, Egan JE, Mitty J, Boverman J, Fiellin DA, BHIVES Collaborative. PMID: 21317601.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    66. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr. 2011 Mar 01; 56 Suppl 1:S83-90. Korthuis PT, Fiellin DA, Fu R, Lum PJ, Altice FL, Sohler N, Tozzi MJ, Asch SM, Botsko M, Fishl M, Flanigan TP, Boverman J, McCarty D, BHIVES Collaborative. PMID: 21317600; PMCID: PMC3066190.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    67. HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco. Vaccine. 2011 Feb 24; 29(10):1991-6. Etcheverry MF, Lum PJ, Evans JL, Sanchez E, de Lazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, Page K, Joseph J. PMID: 21241735; PMCID: PMC3747033.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    68. HIV intervention for providers study: a randomized controlled trial of a clinician-delivered HIV risk-reduction intervention for HIV-positive people. J Acquir Immune Defic Syndr. 2010 Dec 15; 55(5):572-81. Rose CD, Courtenay-Quirk C, Knight K, Shade SB, Vittinghoff E, Gomez C, Lum PJ, Bacon O, Colfax G. PMID: 20827218.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    69. Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Vaccine. 2010 Aug 23; 28(37):5947-51. Levy V, Evans JL, Stein ES, Davidson PJ, Lum PJ, Hahn JA, Page K. PMID: 20638453; PMCID: PMC2936506.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    70. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Addiction. 2010 Jul; 105(7):1254-64. Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K. PMID: 20491725; PMCID: PMC2907461.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    71. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis. 2009 Oct 15; 200(8):1216-26. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch MP. PMID: 19764883; PMCID: PMC2821203.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    72. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). Drug Alcohol Depend. 2009 May 01; 101(3):152-7. Evans JL, Hahn JA, Lum PJ, Stein ES, Page K. PMID: 19181458; PMCID: PMC2692897.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    73. Trends in methamphetamine use in young injection drug users in San Francisco from 1998 to 2004: the UFO Study. Drug Alcohol Rev. 2008 May; 27(3):286-91. Inglez-Dias A, Hahn JA, Lum PJ, Evans J, Davidson P, Page-Shafer K. PMID: 18368610; PMCID: PMC3747037.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    74. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat. 2008 Mar; 15(3):229-36. Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, Moss AR. PMID: 18233994.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    75. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Drug Alcohol Depend. 2008 Jan 11; 93(1-2):43-50. Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ. PMID: 17980513; PMCID: PMC2247437.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    76. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS. 2007 Sep 12; 21(14):1967-9. Page-Shafer K, Hahn JA, Lum PJ. PMID: 17721105.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    77. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS. 2007 Jan 11; 21(2):239-41. Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. PMID: 17197817.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    78. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep. 2006 Nov; 3(4):195-204. Lum PJ, Tulsky JP. PMID: 17089480.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    79. Commercial sex work and risk of HIV infection among young drug-injecting men who have sex with men in San Francisco. Sex Transm Dis. 2006 Apr; 33(4):228-34. Bacon O, Lum P, Hahn J, Evans J, Davidson P, Moss A, Page-Shafer K. PMID: 16565643.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansPHPublic Health
    80. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr. 2006 Jan 01; 41(1):31-6. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, Havlir D, Peters M. PMID: 16340470; PMCID: PMC4050666.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    81. Incarceration among young injectors in San Francisco: associations with risk for hepatitis C virus infection. Journal of Substance Use. 2006 Jan 1; 11(4):271-281. Kittikraisak KW, Davidson DP, Hahn HJ, Lum LP, Evans EJ, Moss MA, Page-Shafer PK. .
      View in: Publisher Site   Mentions:
    82. Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse. 2005; 40(11):1681-96. Lum PJ, Sears C, Guydish J. PMID: 16253934.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    83. LUM ET AL. RESPOND. American Journal of Public Health. 2004 Mar 1; 94(3):358-a-359. Lum LP, Ochoa OK, Hahn HJ, Shafer SK, Evans EJ, Moss MA. .
      View in: Publisher Site   Mentions:
    84. Hepatitis B virus immunization among young injection drug users in San Francisco, Calif: the UFO Study. Am J Public Health. 2003 Jun; 93(6):919-23. Lum PJ, Ochoa KC, Hahn JA, Page Shafer K, Evans JL, Moss AR, UFO Study. PMID: 12773355; PMCID: PMC1447870.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    85. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003 Mar; 80(1):137-46. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, Moss AR. PMID: 12612103; PMCID: PMC3456106.
      View in: PubMed   Mentions: 131     Fields:    Translation:Humans
    86. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr. 2002 Dec 01; 31(4):422-31. Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. PMID: 12447014.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    87. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002 Dec 01; 186(11):1558-64. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. PMID: 12447730.
      View in: PubMed   Mentions: 143     Fields:    Translation:HumansCells
    88. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001 Jul; 34(1):180-7. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. PMID: 11431749.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    89. Investigation of a Secondary Syringe Exchange Program for Homeless Young Adult Injection Drug Users in San Francisco, California, U.S.A. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001 Jun 1; 27(2):193-201. Sears SC, Guydish GJ, Weltzien WE, Lum LP. .
      View in: Publisher Site   Mentions:
    90. Investigation of a Secondary Syringe Exchange Program for Homeless Young Adult Injection Drug Users in San Francisco, California, U.S.A. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2001 Jun 1; 27(2):193-201. Sears SC, Guydish GJ, Weltzien WE, Lum LP. .
      View in: Publisher Site   Mentions:
    Paula's Networks
    Concepts (251)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (64)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.